Dr Reddys Ownership
| RDY Stock | USD 13.71 0.13 0.96% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 4.2 B | Current Value 834 M | Avarage Shares Outstanding 884 M | Quarterly Volatility 418.7 M |
RDY |
RDY Stock Ownership Analysis
About 15.0% of the company shares are owned by institutional investors. The book value of Dr Reddys was at this time reported as 381.36. The company last dividend was issued on the 30th of July 2024. Dr Reddys Laboratories had 5:1 split on the 5th of November 2024. Reddys Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 24795 people. To find out more about Dr Reddys Laboratories contact MARC KIKUCHI at 91 40 4900 2900 or learn more at https://www.drreddys.com.Besides selling stocks to institutional investors, Dr Reddys also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Dr Reddys' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Dr Reddys' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Dr Reddys Quarterly Liabilities And Stockholders Equity |
|
RDY Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Dr Reddys is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Dr Reddys Laboratories backward and forwards among themselves. Dr Reddys' institutional investor refers to the entity that pools money to purchase Dr Reddys' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jpmorgan Chase & Co | 2024-12-31 | 2.8 M | Fisher Asset Management, Llc | 2024-12-31 | 2.5 M | Gqg Partners Llc | 2024-12-31 | 2 M | Bank Of America Corp | 2024-12-31 | 1.9 M | Jane Street Group Llc | 2024-12-31 | 1.5 M | Northern Trust Corp | 2024-12-31 | 1.4 M | Goldman Sachs Group Inc | 2024-12-31 | 1.2 M | Geode Capital Management, Llc | 2024-12-31 | 1.2 M | Old Mission Capital Llc | 2024-12-31 | 1.1 M | Robeco Institutional Asset Management Bv | 2024-12-31 | 11.4 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 11.3 M |
Dr Reddys Outstanding Bonds
Dr Reddys issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Dr Reddys Laboratories uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most RDY bonds can be classified according to their maturity, which is the date when Dr Reddys Laboratories has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Dr Reddys Corporate Filings
6K | 21st of March 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for RDY Stock Analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.